Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

BACKGROUND: Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. METHODS: Postmenopausal women with ER-positi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:BMC Cancer
Autori principali: Wu, Wei, Chen, Jiewen, Deng, Heran, Jin, Liang, He, Zhanghai, Rao, Nanyan, Nie, Yan, Yao, Yandan, Yang, Yaping, Su, Fengxi, Liu, Jieqiong
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2021
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8317384/
https://ncbi.nlm.nih.gov/pubmed/34315439
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08612-y
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi